1,032 results on '"Elborn, J. Stuart"'
Search Results
2. Airway inflammation accelerates pulmonary exacerbations in cystic fibrosis
3. Longitudinal changes in the cystic fibrosis airway microbiota with time and treatment
4. Analysis of SARS-CoV-2 antibody seroprevalence in Northern Ireland during 2020–2021
5. Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC)
6. Omalizumab in Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis
7. An invisible threat? Aspergillus positive cultures and co-infecting bacteria in airway samples
8. Bronchiectasis and inhaled tobramycin: A literature review
9. Randomised, phase 1/2a trial of ION-827359, an antisense oligonucleotide inhibitor of ENaC
10. Airway clearance management in people with bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)
11. In vitro activity of cefiderocol against Gram-negative pathogens isolated from people with cystic fibrosis and bronchiectasis
12. Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis
13. Extended-culture and culture-independent molecular analysis of the airway microbiota in cystic fibrosis following CFTR modulation with ivacaftor
14. Characterization of clinical Ralstonia strains and their taxonomic position
15. Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study
16. Microbial interaction: Prevotella spp. reduce P. aeruginosa induced inflammation in cystic fibrosis bronchial epithelial cells
17. Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis
18. Bronchiectasis and asthma:Data from the European Bronchiectasis Registry (EMBARC)
19. Objective sputum colour assessment and clinical outcomes in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)
20. Finding the relevance of antimicrobial stewardship for cystic fibrosis
21. Influence of azithromycin and allograft rejection on the post–lung transplant microbiota
22. Antisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosis
23. Immunodeficiency in Bronchiectasis
24. Assessment of stability and fluctuations of cultured lower airway bacterial communities in people with cystic fibrosis
25. Speeding up access to new drugs for CF: Considerations for clinical trial design and delivery
26. CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials
27. Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis
28. Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review
29. Analysis of SARS-CoV-2 Ig seroprevalence in Northern Ireland
30. Regulatory T cells mediate the decreased susceptibility of males to Pseudomonas aeruginosa infection
31. Effect of treatment with tobramycin on the airway microbiota and resistome in bronchiectasis patients chronically colonised with Pseudomonas aeruginosa: iBEST study
32. Pseudomonas aeruginosa eradication in patients with bronchiectasis: data from the EMBARC registry
33. Cardiovascular complications of cystic fibrosis
34. Defining antimicrobial resistance in cystic fibrosis
35. Cystic fibrosis epithelial cells are primed for apoptosis as a result of increased Fas (CD95)
36. Ciprofloxacin Dry Powder for Inhalation (ciprofloxacin DPI): Technical design and features of an efficient drug–device combination
37. El papel de los antibióticos inhalados en la era de los moduladores de CFTR de alta eficacia
38. Bridging the “Know-Do” Gaps in Five Non-Communicable Diseases Using a Common Framework Driven by Implementation Science
39. Activity of innate antimicrobial peptides and ivacaftor against clinical cystic fibrosis respiratory pathogens
40. Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial
41. Bacterial proteases and haemostasis dysregulation in the CF lung
42. New strategies of physical activity assessment in cystic fibrosis: a pilot study
43. Lung function and microbiota diversity in cystic fibrosis
44. Electronic cigarette vapour increases virulence and inflammatory potential of respiratory pathogens
45. Lung Clearance Index in Adults and Children With Cystic Fibrosis
46. Clinimetric Properties of Outcome Measures in Bronchiectasis
47. Bridging the “Know-Do” Gaps in Five Non-Communicable Diseases Using a Common Framework Driven by Implementation Science
48. Cystic fibrosis
49. Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients With Cystic Fibrosis: Systematic Literature Review and Network Meta-analysis
50. Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.